Eli Lilly and Company EPS Ratio 2011-2026 | LLY

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Eli Lilly and Company

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
23	11.8	5.82	6.93	6.15	6.82	8.93	3.14	-0.19	2.59	2.27	2.23	4.33	3.67	3.9

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
23	-0.19	6.09

Quarterly EPS Ratio Eli Lilly and Company

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
6.3	3.07	1.08	3.29	2.49	-0.06	1.96	1.49	-	1.61	1.06	2.11	-	1.22	1.53	1.49	-	1.33	1.56	1.6	1.64	1.37	1.44	4.33	1.11	1.13	-0.25	1.16	-1.58	0.53	0.96	-0.1	0.73	0.74	0.71	0.42	0.45	0.75	0.57	0.5	0.4	0.47	0.68	0.68	0.68	1.11	1.12	1.42	0.75	1.18	0.83	0.91	-	1.11	1.07	0.95

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.3	-1.58	1.21

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	-0.49	$ 3.44	-4.32 %	$ 1.03 B	Canada
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
ADMA Biologics ADMA	0.62	$ 15.36	-2.17 %	$ 3.66 B	USA
Cellectis S.A. CLLS	-2.55	$ 3.53	-3.54 %	$ 116 M	France
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
Apellis Pharmaceuticals APLS	0.18	$ 20.28	0.65 %	$ 2.56 B	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Nymox Pharmaceutical Corporation NYMX	-0.15	-	-19.68 %	$ 18.4 M	Canada
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA
Aptorum Group Limited APM	-0.78	$ 0.79	-1.15 %	$ 4.31 M	China
Autolus Therapeutics plc AUTL	-0.86	$ 1.51	1.35 %	$ 385 M	Britain
China SXT Pharmaceuticals SXTC	-2.32	$ 2.01	-1.36 %	$ 2.86 M	China
Galmed Pharmaceuticals Ltd. GLMD	8.08	$ 0.67	7.08 %	$ 624 K	Israel
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Anika Therapeutics ANIK	-5.64	$ 14.05	-1.44 %	$ 206 M	USA
ANI Pharmaceuticals ANIP	-1.04	$ 74.36	-1.64 %	$ 1.44 B	USA
Applied Therapeutics APLT	-1.42	-	-	$ 8.42 M	USA
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Athersys ATHX	-0.39	-	3.77 %	$ 22.4 M	USA
AVEO Pharmaceuticals AVEO	-1.63	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-3.68	$ 162.43	0.6 %	$ 8.08 B	USA
BioCryst Pharmaceuticals BCRX	-0.43	$ 8.49	-0.18 %	$ 1.75 B	USA
BridgeBio Pharma BBIO	-3.78	$ 65.66	-0.78 %	$ 12.6 B	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Brainstorm Cell Therapeutics BCLI	-2.31	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
Bellerophon Therapeutics BLPH	-2.08	-	-74.18 %	$ 955 K	USA
Bellicum Pharmaceuticals BLCM	-0.81	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-1.42	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
BioLineRx Ltd. BLRX	-0.12	$ 2.69	-0.74 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	1.82	$ 61.3	1.21 %	$ 11.8 B	USA
Burford Capital Limited BUR	75.3	$ 7.79	-5.75 %	$ 1.28 B	Britain
CymaBay Therapeutics CBAY	-0.99	-	-	$ 3.45 B	USA